Liver transplantation after radioembolization in a patient with unresectable HCC

被引:11
作者
Moreno Luna, Laura E. [1 ]
Kwo, Paul Y. [4 ]
Roberts, Lewis R. [2 ]
Mettler, Teresa A. [2 ]
Gansen, Denise N. [3 ]
Andrews, James C. [3 ]
Wiseman, Gregory A. [3 ]
Misra, Vijay Laxmi [4 ]
机构
[1] Univ Guadalajara, Dept Med, Guadalajara 44430, Jalisco, Mexico
[2] Mayo Clin, Dept Med, Miles & Shirley Fiterman Ctr Digest Dis, Rochester, MN USA
[3] Mayo Clin, Dept Radiol, Rochester, MN USA
[4] Indiana Univ, Dept Med, Div Gastroenterol Hepatol, Clarian IU Digest Dis Ctr,Sch Med, Indianapolis, IN USA
关键词
HEPATOCELLULAR-CARCINOMA; Y-90; MICROSPHERES; UNITED-STATES; SURVIVAL; CANCER; TRENDS;
D O I
10.1038/nrgastro.2009.165
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. A 58-year-old white man who was being followed by his hepatologist for nonalcoholic steatohepatitis-related liver cirrhosis and portal hypertension and who had been found to have a biopsy-proven hepatocellular carcinoma (HCC) on routine screening, self-referred to our center for a second opinion on the management of his HCC. Investigations. Laboratory investigations, CT scan of the abdomen and chest, bone scan and technetium macroaggregated albumin scan. Diagnosis. The patient had unresectable HCC. Management. The patient underwent two treatments with Yttrium-90 glass microspheres, which were performed as outpatient procedures 1 month and 3 months after diagnosis. He underwent orthotopic liver transplantation (OLT) 1 year after the initial diagnosis of HCC. The post-OLT immunoregimen included OKT3 plus rituximab and high-dose steroids. On discharge from hospital he was on immunosuppressive treatment with tacrolimus. He had de novo autoimmune hepatitis 6 months post-OLT, which was treated with a short course of low-dose steroids and addition of mycophenolate mofetil.
引用
收藏
页码:679 / 683
页数:5
相关论文
共 19 条
[1]   Treatment options for hepatobiliary and pancreatic cancer [J].
Alberts, Steven R. ;
Gores, Gregory J. ;
Kim, George P. ;
Roberts, Lewis R. ;
Kendrick, Michael L. ;
Rosen, Charles B. ;
Chari, Suresh T. ;
Martenson, James A. .
MAYO CLINIC PROCEEDINGS, 2007, 82 (05) :628-637
[2]   Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[3]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[4]   Prognostic prediction and treatment strategy in hepatocellular carcinoma [J].
Bruix, J ;
Llovet, JM .
HEPATOLOGY, 2002, 35 (03) :519-524
[5]  
Carr Brian I, 2004, Liver Transpl, V10, pS107, DOI 10.1002/lt.20036
[6]   The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update [J].
El-Serag, H ;
Davila, JA ;
Petersen, NJ ;
McGlynn, KA .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (10) :817-823
[7]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[8]   The quandary over liver transplantation for hepatocellular carcinoma: The greater sin? [J].
Fung, J ;
Marsh, W .
LIVER TRANSPLANTATION, 2002, 8 (09) :775-777
[9]   Yttrium-90 microspheres for the treatment of hepatocellular carcinoma [J].
Geschwind, JFH ;
Salem, R ;
Carr, BI ;
Soulen, MC ;
Thurston, KG ;
Goin, KA ;
Van Buskirk, M ;
Roberts, CA ;
Goin, JE .
GASTROENTEROLOGY, 2004, 127 (05) :S194-S205
[10]   Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities [J].
Goin, JE ;
Salem, R ;
Carr, BI ;
Dancey, JE ;
Soulen, MC ;
Geschwind, JFH ;
Goin, K ;
Van Buskirk, M ;
Thurston, K .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (02) :205-213